Health
Affinity’s COVID-19 antibodies ready for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19.
This can be found at the link,’Anti…
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News16 hours agoGood character references restricted in rape cases in Queensland
-
General13 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News22 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up